samedan logo

 
 
spacer
home > ebr > winter 2003 > future of electronic data capture in clinical trials
PUBLICATIONS
European Biopharmaceutical Review

Future of Electronic Data Capture in Clinical Trials

Clinical trials currently account for approximately 70 per cent of the US$403 million cost involved in bringing a new drug to market. This makes them an obvious target for those wanting to reduce drug discovery and development costs. The following scenario takes place in the future and suggests how technology may change the process.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tony Dean, Director of Sales and Marketing at Datatrial Ltd

Tony Dean is Director of Sales and Marketing at Datatrial, a biometrics CRO. Tony graduated in Applied Biology and began working in the pharmaceutical industry in 1979 with SK&F, working at the bench in drug metabolism and pharmacokinetics. He subsequently moved into the CRO sector and held various positions within clinical project management prior to moving into business development five years ago.

spacer
Tony Dean
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nova Biomedical Launches BioProfile® FLEX2 On-Line Autosampler for Fully Automated Sampling, Analysis, and Feedback Control of up to 10 Bioreactors

Waltham, MA – Nova Biomedical is pleased to announce the launch of the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to 3 weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. The FLEX2 measures up to 16 tests including pH, gases, metabolites, osmolality, cell density, and cell viability.
More info >>

White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement